- Home
- CTRM vs CALC Comparison
CTRM vs CALC Comparison
Compare CTRM & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- CALC
- Stock Information
- Founded
- CTRM 2016
- CALC 2011
- Country
- CTRM Cyprus
- CALC United States
- Employees
- CTRM N/A
- CALC 15
- Industry
- CTRM Marine Transportation
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- CALC Health Care
- Exchange
- CTRM Nasdaq
- CALC Nasdaq
- Market Cap
- CTRM 22.9M
- CALC 22.9M
- IPO Year
- CTRM N/A
- CALC N/A
- Fundamental
- Price
- CTRM $2.15
- CALC $1.56
- Analyst Decision
- CTRM
- CALC Strong Buy
- Analyst Count
- CTRM 0
- CALC 3
- Target Price
- CTRM N/A
- CALC $16.33
- AVG Volume (30 Days)
- CTRM 77.7K
- CALC 22.6K
- Earning Date
- CTRM 08-07-2025
- CALC 08-11-2025
- Dividend Yield
- CTRM N/A
- CALC N/A
- EPS Growth
- CTRM N/A
- CALC N/A
- EPS
- CTRM 0.38
- CALC N/A
- Revenue
- CTRM $66,243,379.00
- CALC N/A
- Revenue This Year
- CTRM N/A
- CALC N/A
- Revenue Next Year
- CTRM N/A
- CALC N/A
- P/E Ratio
- CTRM $5.56
- CALC N/A
- Revenue Growth
- CTRM N/A
- CALC N/A
- 52 Week Low
- CTRM $1.98
- CALC $1.43
- 52 Week High
- CTRM $5.49
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- CTRM 42.49
- CALC 32.78
- Support Level
- CTRM $2.09
- CALC $1.48
- Resistance Level
- CTRM $2.33
- CALC $1.79
- Average True Range (ATR)
- CTRM 0.14
- CALC 0.12
- MACD
- CTRM -0.03
- CALC -0.02
- Stochastic Oscillator
- CTRM 12.77
- CALC 0.00
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.